It is thus possible that the need for an improved stem cell mobilizing agent "remained unmet despite the obviousness of the [method] claimed in the ['590 Patent]." Acorda Therapeutics, Inc. v. Roxane Labs., Inc., No. 14-882, 2017 WL 1199767, at *40 (D. Del. Mar. 31, 2017). It is speculative, however, that the need would have been solved any sooner had those blocking patents not existed, given the complex and uncertain state of the art in September 2000.